Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Sileo (Dexmedetomidine Oromucosal Gel) for Canine Noise Aversion: Dosing, Efficacy, and Safety
Sileo (dexmedetomidine oromucosal gel) is the first and only FDA-approved treatment for canine noise aversion — an alpha-2 agonist absorbed transmucosally, dosed by weight as syringe "dots" and given shortly before or at the onset of an anticipated noise event. This hub covers label dosing, the pivotal RCT, adverse effects, contraindications, and where it sits against trazodone, clonidine, tasipimidine, and daily SSRIs.
Read →Clonidine for Dogs: Off-Label Alpha-2 Agonist for Noise Aversion, Storm Phobia, and Situational Anxiety
Clonidine is a human alpha-2 adrenergic agonist used off-label in dogs as a short-acting, event-based adjunct for situational fear and anxiety — noise aversion, storm phobia, separation-related distress, fear reactivity, and vet-visit anxiety — layered on a daily SSRI or TCA plus behavior modification rather than run as standalone monotherapy. This hub summarizes the off-label dosing (~0.01–0.05 mg/kg PO), the limited open-label efficacy evidence, adverse effects, contraindications and interactions, and where clonidine sits relative to the FDA-approved event drug dexmedetomidine oromucosal gel (Sileo), trazodone, and gabapentin.
Read →Clomipramine (Clomicalm) for Dogs and Cats: Behavioral Dosing, Efficacy, and Safety
Clomipramine is a tricyclic antidepressant FDA-approved (Clomicalm) as an adjunct to behavior modification for canine separation anxiety, and used off-label for feline urine marking and canine/feline compulsive disorders. This hub covers species-specific dosing, the registration and compulsive-disorder RCTs, adverse effects, MAOI/serotonergic interactions, and where it sits versus fluoxetine, trazodone, and buspirone.
Read →Buspirone for Cats: Urine Spraying, Anxiety, and Off-Label Use in Feline Behavioral Medicine
Buspirone is a non-sedating azapirone (5-HT1A partial agonist) used off-label in cats, best supported for urine spraying/marking in multi-cat households and for generalized, social, and fear-based anxiety. Onset is 1–4 weeks, so it is a maintenance adjunct — not a rescue for acute situational anxiety.
Read →Trazodone for Dogs: Situational Anxiety and Post-Op Confinement Dosing
A clinical reference for prescribing trazodone in dogs: SARI mechanism, off-label status, situational and post-operative confinement dosing, onset, adverse effects, and serotonin syndrome risk with concurrent SSRIs and MAOIs.
Read →Fluoxetine (Reconcile) for Canine Behavior Disorders
Clinical reference on fluoxetine (Reconcile/Prozac) for dogs: FDA-approved separation-anxiety indication, 1-2 mg/kg dosing, 4-6 week onset, adverse effects, and the MAOI/amitraz and serotonin-syndrome interactions every prescriber must screen for.
Read →Gabapentin for Pre-Visit Feline Anxiety: Evidence and Clinical Use
The evergreen clinical reference on gabapentin in cats: randomized and systematic-review evidence for pre-visit anxiolysis, the ~40% ataxia rate and 8-hour resolution window, cardiovascular safety, the pregabalin comparison, and the emerging atopic-dermatitis adjunct signal.
Read →Tasipimidine (Tessie) for Noise Aversion and Separation Anxiety in Dogs
First FDA-approved drug for both noise aversion and separation anxiety in dogs. Alpha-2 agonist mechanism, oral solution, May 2026 approval.
Read →